Molecular Testing at Point of Care: Lessons from the Past, Best Practices Now, Future Prospects

Sheldon Campbell, MD, FCAP
Professor of Laboratory Medicine at Yale School of Medicine
Director, Medical Studies, Laboratory Medicine

November 1, 2022
Sheldon Campbell, MD, FCAP

• Yale School of Medicine
  - Professor of Laboratory Medicine
  - Director, Medical Studies, Laboratory Medicine
  - Director, Medical Microbiology Course
  - Director, Laboratories at VA CT Healthcare System

• College of American Pathologists
  - Member of CAP Point of Care Testing Committee
  - Past Member of CAP Microbiology Resource Committee and Checklist Committee
Learning Objectives

• Participants will be able to:
• Relate the history of point of care testing to current practice; from ancient uroscopy to current molecular tests.
• Describe the core workflow of point-of-care molecular tests
• Analyze quality practices for point of care molecular testing.
• Recognize the relationship of molecular and antigen tests for diagnosis of respiratory infections
• Recognize drivers of molecular POCT in the future
History

“They say the dead can’t speak, but they can! The people in this book died over sixty years ago, in the middle of the ocean, with no one around them for miles, but they still speak to you. They still send us messages—about love and courage and death! That’s what history is, and science, and art. That’s what literature is. It’s the people who went before us, tapping out messages from the past, from beyond the grave, trying to tell us about life and death! Listen to them!”

— Connie Willis, Passage
Uroscopy as POC in the Ancient World

A Sumerian Syllbarium (dictionary) c. 4000 BCE lists body parts, and alludes to changes in color and constitution of urine observed by physicians.

I. 𒈹𒍂 explained as sinatu pizu, “white or pure urine.”

II. 𒊩𒈹 explained as sinatu zaimi, “black or dark urine.”

III. 𒊩𒈨 or 𒊩𒇽 explained as urpāti sinatu, “clouds of the urine.”

IV. 𒊩𒇽 (lost). Explained as tidu sa sinatu, “mud or sediment of the urine.”

V. 𒊩𒈠 explained as sinatu bursi.

This is a very interesting group, as the second square means “bright, very bright red,” and evidently indicates blood-coloured urine.

No, I was not personally around for this.
Some Sanskrit Diagnoses:

- *Iksumeha*, cane-sugar juice urine.
- *Ksuermeha*, potash urine.
- *Sonitameha*, urine containing blood.
- *Pistameha*, floury-white urine.
  - When the patient passes this type of urine the hair on the body becomes erect, and the urine looks as though mixed with flour. Urination is painful.
- *Hastimeha*, elephant urine.
  - “The patient continuously passes turbid urine like a mad elephant.”
- *Madhumeha*, honey urine.
  - Trains of long black ants are attracted by the urine.
Advances in Urine Analysis

• Theophilus (610-641 AD) employed heat to further the analysis of urine; arguably the first analytic technique in medicine.

• Alsahavarius (c. 1085) noted the effect of certain foods on the color of the urine, and cautioned physicians against being fooled by intentional ingestions.

• Actuarius (d. 1283) recommended the use of a graduated glass for measuring sediments.
Specimen Guidelines

- Ismail of Jurjani (c. end of 11th century), a Persian physician
  - Includes container specifications, time of collection, storage conditions, and patient instructions.
  - Goes on to provide detailed recommendations for examination of urine.

> “The urine which is for the physician to examine,” he states, “must be collected in a bottle, which must be large, transparent and clean, and if possible should be in the shape of a bladder. It should be of a large size, so as to contain the whole of the urine (24 hours), for the reason, if there be something (sediment) in it, it should be detected at once. The shape of the bottle is devised like a bladder for the reason that the urine should be in natural position as in that viscus. Urine should be well guarded against heat, cold and the sun, because extremes of temperature change its natural state, and heat makes it burn, and its thin sediments are consumed thereby. Cold makes urine congealed.

> “Urine sent for examination should be that of the early morning after a good sleep. It should be passed before eating or drinking anything, because partaking of certain foods changes the colour of the urine. One should not rely upon urine that has been passed during starvation, sorrow, weakness or sleeplessness, or after coition, because above conditions change its colour. After food and wine the natural heat of the body increases for the purpose of digestion, the urine becomes colourless. Often in hot diseases it becomes white and puts the physician off his guard. After hunger, sleeplessness, sorrow and trouble, urine changes its colour, because heat (bodily) in such conditions moves about (in the body) and makes the urine appear coloured. Often one passes colourless urine after sleeplessness, because heat (bodily) is dissipated through insomnia, the urine passed is rather turbid and not clear and light, because food cannot be well digested in sleeplessness; food remains kham (uncooked, unassimilated); that is also the reason why one gets darkish and muddy water from uncooked food.”
Gilles de Corbeil, who graduated at the School of Salerno at the beginning of the twelfth century, and was first physician to Phillipe Auguste, wrote an elaborate poem on the urine, entitled "Liber de urinis," which gives a good idea of the state of medical knowledge at the period in which he lived. He begins by studying the etymology of the word urine, and then, referring to the composition of this excretion, remarks that "urine is composed of the residue left in the blood and other humours in the kidneys." Next, he proceeds to lay down in detail, rules for its examination, placing, for the guidance of the uroscopist, special emphasis on the aspects, the consistence, the quantity, the nature, and the things contained therein. He enjoins the physician to take into consideration, also, the circumstances of place, the number, the time, the age, the sex, the exercises indulged in, as well as the temperament and diet of his patient.

Poem written in dactylic hexameter, which I dare anyone here to write a scientific publication in today.
Historical Attempts to Comply with Regulations

The urine-glass disc was used as a colorimetric standard (the first ones known date from 1400 or before) in urine diagnosis.

History of Uroscopy – Lessons

- Like us, the ancient uroscopists:
  - Paid attention to pre-analytical, analytical, and post-analytical components of testing.
  - Attempted to standardize procedures and practices
  - Attempted to train, and assess and ensure competency
  - Attempted to improve the practice of their craft
The Modern Era of POCT: Rapid Antigen Tests

• For infectious disease, the first antigen tests for POC use were rapid strep latex tests.
• Required a simple extraction followed by latex agglutination on a glass slide.
• WHY Group A Strep!!?
  • A single test allows for treatment.
  • Limited differential
  • No need for imaging or other tests to complete the encounter.


© 2022 College of American Pathologists. All rights reserved.
Molecular Testing

We've been merging with tools since the beginning of human evolution, and arguably, that's one of the things that makes us human beings.

-Franklin Foer
A Breakthrough in Testing!

A physician examining a urine specimen in which a faint figure of a baby is visible, a female patient is crying and being shouted at by her angry mother, indicating that she is pregnant.

Epdd3r3s. Wellcome Collection.
https://wellcomecollection.org/images?query=epdd3r3s

© 2022 College of American Pathologists. All rights reserved.
What is Molecular Diagnostics?

• Molecular diagnostics have found widespread application with the advent of *amplification methods* (PCR and related approaches).

• Huge scope
  - From single-target molecular detection of pathogens…
  - To pharmacogenomic analysis of metabolism genes for drug dosing…
  - To whole genome sequencing for disease susceptibility and everything else.
Molecular Diagnostic Testing

Specimen
- Specimen type important specimen integrity is crucial.

DNA/RNA Extraction
- Extraction steps simple for easy specimen types; more elaborate for stool, etc.

Amplification of Target
- Many amplification technologies available; thermal cycling vs isothermal

Detection of Amplified Material

Interpretation and Clinical Use
Managing POC Molecular

All the usual QC and QA, plus:

Interferences

- Extraction efficiency
- Inhibition by
  - Blood
  - DNA
- Internal amplification / extraction controls
- Interferences in other testing, maybe more in molecular

Contamination

- Extraordinarily sensitive methods
- Specimen cross-contamination
  - Native material transferred from a positive to a negative specimen
  - Collection devices
  - Ports, racks, hands
- Amplicon contamination
  - From amplified material
  - How well is the product contained?
  - Waste disposal
- Molecular people are very aware of this; lab people are pretty aware of this, clinical/POC people are entirely unaware of this.
## CAP Checklist Items – POC Molecular Testing

<table>
<thead>
<tr>
<th>Title</th>
<th>What it is</th>
<th>Checklist Item</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quality Monitoring Statistics</td>
<td>Detecting contamination by monitoring positivity rates</td>
<td>POC.08675</td>
<td>Phase I</td>
</tr>
<tr>
<td>Specimen Handling Procedures</td>
<td>How do you make sure you get clinically-relevant specimens?</td>
<td>POC.08690</td>
<td>Phase II</td>
</tr>
<tr>
<td>Safe Specimen Handling/Processing</td>
<td>You’re testing for bad things – how do you keep people from catching them?</td>
<td>POC.08715</td>
<td>Phase II</td>
</tr>
<tr>
<td>Final Report</td>
<td>Different methods perform differently, people have to know which you used.</td>
<td>POC.08730</td>
<td>Phase I</td>
</tr>
</tbody>
</table>
Monitoring for False-Positives

- There are written procedures to monitor for the presence of false positive results (eg, due to nucleic acid contamination) for all molecular microbiology tests.

- What do you do if:
  - Your rate of influenza positives jumps to 10% in the middle of the summer?
  - You have three positives in a single run with a test that normally generates one positive every week?
  - In the middle of a COVID spike, you have no positives for three days in a row?

- Think about what to monitor, and what actions to take in response.
## Specimen Integrity

<table>
<thead>
<tr>
<th>Title</th>
<th>What it is</th>
<th>Checklist Item</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specimen Handling Procedures</td>
<td>How do you make sure you get clinically-relevant specimens?</td>
<td>POC.08690</td>
<td>Phase II</td>
</tr>
</tbody>
</table>

- There are written procedures to prevent specimen loss, alteration, or contamination during collection, transport, processing and storage.
- Specimen loss: is that relevant to POC? When?
- Specimen alteration: Can it get hot or cold? Could the transport media deteriorate?
- Contamination: How might this happen between specimens?
- Transport: When is it relevant to POC?
- Processing: Could specimens be lost or cross-contaminate?
- Storage: Where do you keep specimens if testing doesn’t happen immediately, so they’re not lost, harmed, or mixed up?
Safety

<table>
<thead>
<tr>
<th>Title</th>
<th>What it is</th>
<th>Checklist Item</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safe Specimen Handling/Processing</td>
<td>You’re testing for bad things – how do you keep people from catching them?</td>
<td>POC.08715</td>
<td>Phase II</td>
</tr>
</tbody>
</table>

- There are written policies and procedures for the safe handling and processing of specimens, including those suspected to contain highly infectious pathogens.
- You need a plan!!
- OK, so maybe the policy says ‘run in circles screaming’. At least you know what to do, right?
  - (No, that’s not a recommendation.)
  - Think about it ahead of time!
  - How could collection/testing personnel be exposed?
  - What PPE should be used?
  - What environmental/engineering controls do you need?
  - What are safe work practices for the hazards you anticipate?
# Report the Method

<table>
<thead>
<tr>
<th>Title</th>
<th>What it is</th>
<th>Checklist Item</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Final Report</td>
<td>Different methods perform differently, people have to know which you used.</td>
<td>POC.08730</td>
<td>Phase I</td>
</tr>
</tbody>
</table>

- The final report includes a summary of the test method and information regarding clinical interpretation if appropriate.
- Different methods for POC testing – especially antigen vs molecular, but even different molecular tests – can have markedly different sensitivity/specificity/interferences.
Molecular POCT in The Broader Diagnostics Context

Never make predictions, especially about the future.
- Casey Stengel
Molecular Testing for Respiratory Pathogens in 2019…

• Real-time molecular methods can provide result in <1h.
• Molecular methods as a class exceed culture in sensitivity (probably due to viral loss in transport)
• Detection properties vary from system to system.
• Moderately to very expensive equipment
• Clearly the ‘gold standard’ (cue ominous music…)
Where We Stood in Late 2019

- Molecular testing for respiratory viruses was standard-of-care.
- Automated readers for antigen tests improved performance, but not to the level of molecular tests.
  - Antigen tests were on the way out?
COVID-19

- Global pandemic; began in Wuhan, Hubei Province, China, in late 2019.
- Caused by SARS-CoV-2 coronavirus.
- Has since spread worldwide, with in excess of 6 million deaths so far.

Cumulative confirmed COVID-19 deaths by world region. Our World in Data.
https://ourworldindata.org/grapher/cumulative-covid-deaths-region
Impact of COVID-19 Pandemic

- **Globally**
  - In the first three months of 2020 the G20 economies fell 3.4% year-on-year.
  - Between April and June 2020, an equivalent of 400 million full-time jobs were lost across the world.
  - Income earned by workers globally fell 10 percent in the first nine months of 2020, equivalent to a loss of over US$3.5 trillion.

- **In 2020, the U.S. GDP contracted at a 3.5% annualized rate.** It was the biggest contraction since 1946 and the first contraction since 2009.
POC In the COVID Pandemic  
(Controversial, like everything else)

- **Molecular**
  - Sensitive, maybe too sensitive.
  - Expensive when lots of tests needed.
  - Labs are connected to LIS and report to public health.

- **Antigen**
  - Insensitive; except maybe not.
  - Cheap, except not really.
  - Home-based testing is widely and rapidly available.

---

My daughter’s (+) COVID test; did not get reported to public health. Did get loaded to Instagram.
SCIENCE ADVANCES | RESEARCH ARTICLE

Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening

Daniel B. Larremore1,2,*, Bryan Wilder3, Evan Lester4,5, Soraya Shehata5,6, James M. Burke4, James A. Hay7,8, Milind Tambe3, Michael J. Mina3,7,9, Roy Parker4,6,10,11

The COVID-19 pandemic has created a public health crisis. Because SARS-CoV-2 can spread from individuals with presymptomatic, asymptomatic infections, the reopening of societies and the control of virus spread will be facilitated by robust population screening, for which virus testing will often be central. After infection, individuals undergo a period of incubation during which viral titers are too low to detect, followed by exponential viral growth, leading to peak viral load and infectiousness and ending with declining titers and clearance. Given the pattern of viral load kinetics, we model the effectiveness of repeated population screening considering test sensitivities, frequency, and sample-to-answer reporting time. These results demonstrate that effective screening depends largely on frequency of testing and speed of reporting and is only marginally improved by high test sensitivity. We therefore conclude that screening should prioritize accessibility, frequency, and sample-to-answer time; analytical limits of detection should be secondary.

Fig. 6. Repeated population screening suppresses an ongoing epidemic. Widespread testing and isolation of infected individuals drive prevalence downward for both (A) the fully mixed compartmental model and (B) the agent-based model. Time series of prevalence, measured as the total number of infectious individuals, are shown for no intervention (solid) and population screening scenarios (various dashed lines; see legend) for individual stochastic simulations. Screening began only when prevalence reached 4% (box), and time series are shifted such that testing begins at \( t = 0 \). Scenarios show the impact of a test with LOD \( 10^5 \), no delay in results, and with 10% of samples assumed to be incorrectly collected (and therefore negative) to reflect decreased sensitivity incurred at sample collection in a mass testing scenario. Annotations show total number of post-intervention infections, as a percentage of the no-intervention scenario, labeled as 100% (see fig. S8 for identical simulations using a test with LOD \( 10^6 \)).

© 2022 College of American Pathologists. All rights reserved.
Dilemmas

- Causes of late Ct (low-level) positives:
  - Timing of specimen collection
  - Antiviral therapy
  - Specimen type / quality / stability
  - PCR inhibitors
More Considerations…

- Symptomatic persons at any Ct value considered infected; viral shedding varies.
- Immunosuppressed persons often shed longer.
- If low prevalence, false-positives are relatively more common.
- Retesting can be problematic; around and below the test LoD positives are not necessarily reproducible.
- Clinical vs analytical specificity
Characteristics of Direct Tests

- Published April 29, 2022
- 225 patients
- All infections confirmed by RT-PCR
RT-PCR Vs Antigen Vs Culture

- RT-PCR more sensitive early and late in infection.
  - Stays positive a long time in a lot of patients.
- Antigen and culture track closely – maybe antigen correlates with infectivity.
  - We’re not likely to get a better measure of this.
Limitations of Antigen Testing

- Antigen is better in symptomatic patients and in the unvaccinated.
(Non) Drivers of POCT: Campbell’s laws of POCT, and Corollaries

The Laws
1. Almost nobody goes into medicine or nursing to do diagnostic testing.
2. No POCT, however simple, is easier than filling in one more box on a laboratory order.

The Inpatient Corollary
An Inpatient POC test is useful only if:
The time for transport to the laboratory for THAT SINGLE ANALYTE significantly and negatively impacts care, OR
The test is performed on an easily obtained sample (e.g., fingerstick blood) MORE FREQUENTLY than routine blood draws are obtained

The Outpatient Corollary
An outpatient POC test is useful only if:
The test result is available during the patient visit AND a decision can be made or action taken on the basis of it without waiting for other laboratory results, OR if you can make money doing it.
### Strengths
- Everything everyone loves about POC
- Not novel to MDs and Pts; accustomed to GAS and Flu Ag tests
- Current assays (e.g. NAAT, more sensitive Ag assays) have improved performance
- Some POC NAAT comparably sensitive to culture and lab-based methods
- Many specimens readily available: urine, mucosal swabs, whole blood

### Weaknesses
- Instrumentation costs
- Assay / Reagent costs
- Specimen type restrictions (e.g. eSwab v. conventional swab)
- Serum or plasma beyond POC scope
- Limited ID conditions where AST is not relevant
- Quality of testing performance by non-laboratory staff.
- Arbitrary / limited menus limit clinical impact
- Small number of analytes per platform limit scalability

### Opportunities
- Continuing advances in testing: NAAT workflow, TAT, “Lab on a Chip”
- Antimicrobial stewardship (AMS) increased importance nationally with regulatory bodies
- Development of biomarkers for AMS → Negative Predictive Value
- Development of new antivirals to broaden clinical actions (e.g. RSV)
- Implementing tests at specific sites (e.g. public health / STI clinics)
- Ability to facilitate new models of care
- Microbiology laboratory consolidation may necessitate more local infectious disease testing

### Threats
- Changes in reimbursement models
- Inertia in physician offices
- Theranos-effect → Disproportionally increased scrutiny of assays / methods and/or disproportionate fear of regulatory oversight for novel tests / methods
- Turf wars between pharmacies, urgent cares, offices, EDs and potential regulation
### Table 1
Microbiological POC in various environments

<table>
<thead>
<tr>
<th>Care Setting</th>
<th>Clinical Environment</th>
<th>Types of Infections and Problems Seen</th>
<th>Turnaround Time for Impact</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inpatient</td>
<td>Clinical laboratory on-site; often clinically complex patients.</td>
<td>Sepsis; HAI.</td>
<td>Transport time to laboratory has to be long enough to make it worthwhile doing the test at the POC.</td>
<td>Wide range of potential pathogens in many cases.</td>
</tr>
<tr>
<td>Emergency</td>
<td>Clinical laboratory on-site</td>
<td>Acute infectious syndromes; some screening.</td>
<td>Test turnaround time strongly impacts throughput.</td>
<td>Tests that can speed discharge strongly favored.</td>
</tr>
<tr>
<td>Urgent care</td>
<td>No dedicated laboratory; test availability impacts scope of care available. Space and personnel limited. Volume of testing must justify capital expenses.</td>
<td>Acute infectious syndromes.</td>
<td>Test turnaround time strongly impacts throughput.</td>
<td>Availability of some tests may allow expansion of scope of care available on-site.</td>
</tr>
<tr>
<td>Ambulatory</td>
<td>POL on site, or only CLIA-waived tests. Space and personnel limited. Volume of testing must justify capital expenses.</td>
<td>Common health maintenance, screening, and acute ambulatory illnesses.</td>
<td>Test results must be available during the encounter to streamline care.</td>
<td></td>
</tr>
<tr>
<td>Telemedicine</td>
<td>Laboratory may or may not be on-site, depending on the telemedicine model.</td>
<td>Common health maintenance, screening, and acute ambulatory illnesses.</td>
<td>Depends on care model.</td>
<td>Evolving models for telemedicine. In some cases will be linked to other services—pharmacy, imaging. Extent of laboratory tests available at POC may impact scope of care.</td>
</tr>
<tr>
<td>Outreach</td>
<td>Specific programs, targeting particular diseases or vulnerable populations. No on-site laboratory; limited, often temporary space.</td>
<td>STI; HIV, HCV.</td>
<td>Rapid—30 min or less for success.</td>
<td></td>
</tr>
<tr>
<td>Home</td>
<td>Patient centered; clinical and interpretive support limited.</td>
<td>STI; acute infectious syndromes; chronic disease screening.</td>
<td>Somewhat flexible; some mail-in testing has been successful.</td>
<td>An evolving area; will expert systems increase the possibilities for home testing?</td>
</tr>
</tbody>
</table>

*Abbreviations: HAI, healthcare-associated infection; HCV, hepatitis C virus; HIV, human immunodeficiency virus; POC, point-of-care; POL, physician’s office laboratory; STI, sexually transmitted infection.*
Information Technology and the Future of POCT

Opportunities

- Outreach to underserved populations via widely available devices, e.g. smartphones.
- Run complex analytics; computer vision, interpretation, NGS data analysis, remotely.
- Rapid reaction to emerging infections.

Challenges

- How can the variety of POCT plug into the EMR and the public health system?
- Development of heterogeneous data universe would be bad.
- Validation of complex multisite testing at POC.
- Security. Also security and security.
The Distant Future

- POCT and changes in care models. Note that POL testing exists in large practices now; how different is this?
- Decentralized testing, along with decentralized imaging and other diagnostic support services, may drive decentralization of care.
- Highly-complex analyses will be laboratory performed for the foreseeable future, but new models of laboratory practice will evolve as decentralized testing becomes more prevalent.
  - However do you manage QC for analyzers in fifty decentralized telemedicine / pharmacy sites?
  - In ten thousand homes?
- POC will still need to close the clinical encounter to have impact; but perhaps the clinical encounter will change, too.
Point-of-Care Programs

- Found in the 2023 Catalog
- Improve waived test results with POC Competency Challenges that
  - Evaluate instrument and method performance
  - Troubleshoot issues
  - Assess staff competency
  - Provide training information
Guide Your Point-of-Care Testing With Confidence

Gain insights with the Point-of-Care Testing Toolkit, an ebook resource for all members of the team. The toolkit covers:

- POCT advantages and disadvantages
- Current and projected technology
- Pathologist, laboratory director, and POCT coordinator roles in POCT
- Selection of appropriate test methods
- Validation and verification protocols
- Quality control and data management
- Patient safety
- POCT training and competency

Purchase the ebook at ebooks.cap.org

© 2022 College of American Pathologists. All rights reserved.
Sources and Acknowledgements

• Much of the discussion and tables are from:

• For information on uroscopy:
  − Melissa Grafe, Ph.D.
    John R. Bumstead Librarian for Medical History
    Cushing/Whitney Medical Library, Yale University
    • Of this 305-page monograph, only the first 92 pages pertain to uroscopy; the rest consists of advertisements for Wellcome products.